2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Phosphorylase
  5. Phosphorylase Inhibitor

Phosphorylase Inhibitor

Phosphorylase Inhibitors (10):

Cat. No. Product Name Effect Purity
  • HY-108615
    CP-316819
    		Inhibitor ≥99.0%
    CP 316819 is a potent glycogen phosphorylase (GPase) inhibitor with antihyperglycemic effect (IC50 values are 17 and 34 nM against human skeletal muscle glycogen phosphorylase (huSMGPa) and liver glycogen phosphorylase (huLGPa) respectively).CP 316819 causes glycogen accumulation under normoglycemic conditions but permits glycogen utilization when glucose concentrations are low.CP-316819 prevents neuronal cell death and maintains brain electrical currents.
  • HY-19396
    Ingliforib
    		Inhibitor 99.07%
    Ingliforib (CP 368296) is a glycogen phosphorylase inhibitor, with IC50s of 52, 352 and 150 nM for liver, muscle and brain glycogen phosphorylase, and has cardioprotective activity.
  • HY-W017441A
    hUP1-IN-1 potassium
    		Inhibitor 99.54%
    hUP1-IN-1 potassium (compound 6a) is a hUP1 inhibitor with Kii and Kis Urd of 375 and 635 nM. hUP1-IN-1 potassium showes inhibitory activities over hUP1 catalyzed reaction with 70% at 1 μM. hUP1-IN-1 potassium can be used for the research of cancer.
  • HY-139140
    BAY R3401
    		Inhibitor
    BAY R3401 is an orally active glycogen phosphorylase inhibitor that can achieve irreversible and non-selective inhibition of hepatic glycogenolysis. BAY R3401 inhibits glycogenolysis in liver cells, with IC50 values of 27.06 and 52.83 μM in HL-7702 and HepG2 cells, respectively. BAY R3401 can be used for the research of type 2 diabetes.
  • HY-W552525
    Deoxyadenosine diphosphate sodium
    		Inhibitor
    Deoxyadenosine diphosphate sodium is a nucleoside diphosphate, in which the nucleoside is deoxyadenosine. Deoxyadenosine diphosphate sodium participates in DNA synthesis and repair. Deoxyadenosine diphosphate sodium acts as the inhibitor of polynucleotide phosphorylase, interfers with the polymerization of ADP and CDP.
  • HY-100320
    AVE5688
    		Inhibitor 98.79%
    AVE5688 is an inhibitor of glycogen phosphorylase (GP), with IC50s of 430 nM and 915 nM and Kds of 170 nM and 530 nM for rabbit muscle glycogen phosphorylase (rmGPb and rmGPa, respectively); AVE5688 can be used for the research of type 2 diabetes.
  • HY-117172
    CP320626
    		Inhibitor
    CP320626 is a potent inhibitor of human liver glycogen phosphorylase (IC50=205 nM). CP320626 reduces blood glucose in diabetic mice without changing plasma insulin levels. CP320626 can be used in the study of type 2 diabetes.
  • HY-128029
    Glycogen phosphorylase-IN-1
    		Inhibitor
    Glycogen phosphorylase-IN-1 (Compound 42) is an inhibitor for human liver glycogen phosphorylase (hlGPa) and hepatocyte glycogen-derived glucose production with IC50s of 53 and 380 nM, respectively. Glycogen phosphorylase-IN-1 reveals efficacy towards type 2 diabetes.
  • HY-127018A
    Maltoheptaose hydrate
    		Inhibitor
    Maltoheptaose hydrate is an activator of phosphorylase B to prepare heptulose-2-phosphate. Maltoheptaose hydrate is a maltooligosaccharide contanins seven glucose units.
  • HY-108614
    GPi688
    		Inhibitor
    GPi688 is a potent and orally active glycogen phosphorylase (GPa) inhibitor with IC50s of 19 nM, 61 nM and 12 nM for human liver GPa, rat liver GPa and human skeletal muscle GPa, respectively. GPi688 can inhibit glucagons-mediated glucose output in rat primary hepatocytes. GPi688 can be used for researching glucagon-mediated hyperglycaemia.